Indian drugmaker Mankind Pharma posts higher quarterly profit on strong chronic drugs demand

Mankind Pharma

03/02/2026 11:10

Feb 3 (Reuters) - Indian drugmaker Mankind Pharma MNKI.NS reported a higher third-quarter profit on Tuesday, driven by strong domestic demand for its drugs used for treating long-term illnesses.

The company, which makes Gas-O-Fast antacid tablet and Manforce condoms, said its consolidated net profit climbed to 4.09 billion rupees ($45.3 million) for the quarter ended December 31, from 3.8 billion rupees a year ago.

Overall revenue rose 11.5% to 35.67 billion rupees, led by a 200-basis-point increase in the market share of its chronic illness drugs in India to 39.3%.

For further earnings highlights, click nFWN3YY1RT.

KEY CONTEXT

The Indian pharmaceuticals market grew 11% in the December quarter, led by strong demand for cardiovascular, anti-diabetic and anti-infective therapies, according to data from India Ratings and Research.

Mankind Pharma said its market share gains in the chronic segent were driven by strong growth in its cardiac and anti-diabetes portfolio, which each expanded 16.7% and 14.4%.

This benefitted the company, which relies on the sales of these drugs and comprise a large part of its revenue.

PEER COMPARISON

Estimates (next 12 months)
Analysts' sentiment
RIC
PE
EV/EBITDA
Revenue growth (%)
Profit growth (%)
Mean rating*
# of analysts
Stock to price target**
Mankind Pharma Ltd
MNKI.NS
34.55
21.51
12.66
24.43
Buy
16
0.78
Torrent Pharmaceuticals Ltd
TORP.NS
47.45
27.08
14.07
20.47
Buy
29
0.98
Glenmark Pharmaceuticals Ltd
GLEN.NS
24.02
14.76
6.56
-3.32
Buy
9
0.88
J B Chemicals and Pharmaceuticals Ltd
JBCH.NS
32.58
21.70
11.83
17.23
Buy
9
0.91

* The mean of analysts' ratings standardised to a scale of Strong Buy, Buy, Hold, Sell, and Strong Sell

** The ratio of the stock's last close to analysts' mean price target; a ratio above 1 means the stock is trading above the PT

OCTOBER TO DECEMBER STOCK PERFORMANCE

-- All data from LSEG

-- $1 = 90.2130 Indian rupees

MNKI v Peers https://tmsnrt.rs/4qPFWAF

 (Reporting by Kashish Tandon in Bengaluru; Editing by Mrigank Dhaniwala)

 ((Kashish.Tandon@thomsonreuters.com; 8800437922;))